Emmanuel Antonarakis, MD
Medical Oncology · Minneapolis, MNNPI 1568528768
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $217,356 of the $259,719 with a category attached, or 83.7%. 28 manufacturers reported payments, led by Merck at 27.0% of the total. Among medical oncology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 212 payments — averaging $1225.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$70K
- Bayer$40K
- Astrazeneca UK Limited$27K
- AstraZeneca$14K
- Pfizer$14K
- Sanofi$12K
- plus $82K from 22 others
Across 301 payments — averaging $21,910 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$2.8M
- Novartis$834K
- Medivation LLC.$721K
- Janssen Research & Development, LLC$624K
- AstraZeneca$461K
- Bayer$312K
- plus $832K from 10 others
What the payments were for
- Consulting fees$217,35684%
- Speaking & faculty fees$22,1459%
- Travel & lodging$15,4886%
- Food & beverage$4,7312%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 48 | $70,002 |
| Bayer | 44 | $40,418 |
| Astrazeneca UK Limited | 17 | $26,989 |
| AstraZeneca | 9 | $14,329 |
| Pfizer | 8 | $14,145 |
| Sanofi | 12 | $11,726 |
| Janssen Scientific Affairs, LLC | 6 | $10,202 |
| Clovis Oncology, Inc. | 4 | $10,145 |
| Menarini Silicon Biosystems, Inc. | 5 | $10,108 |
| Eli Lilly | 18 | $7,929 |
| AbbVie | 11 | $6,009 |
| Amgen | 5 | $5,346 |
| Blue Earth Diagnostics | 2 | $4,500 |
| E.r. Squibb & Sons, L.L.C. | 5 | $3,909 |
| Myovant Sciences Inc. | 1 | $3,875 |
| Janssen Global Services, LLC | 3 | $3,756 |
| Curium US LLC | 2 | $2,713 |
| Genentech, Inc. | 1 | $2,640 |
| Tolmar, Inc. | 1 | $2,500 |
| Advanced Accelerator Applications | 1 | $2,500 |
| Aadi Bioscience, Inc. | 1 | $1,500 |
| Johnson & Johnson | 2 | $1,391 |
| Telix Pharmaceuticals | 1 | $1,300 |
| GSK | 1 | $650 |
| Corcept Therapeutics | 1 | $500 |
| Partner Therapeutics, Inc. | 1 | $450 |
| Astellas Pharma US Inc | 1 | $126 |
| Genentech USA, Inc. | 1 | $61 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYNPARZA$28,955
- Xofigo$21,009
- TALZENNA$13,750
- JEVTANA$11,254
- Rubraca$10,145
- CELLSEARCH$10,108
- Nubeqa$9,251
- Erleada$8,554
- Non-Covered$7,239
- ORGOVYX$3,875
- Deparray$3,539
- OPDIVO$2,700
- 64Cu-PSMA-I&T$2,700
- 177Lu-PSMA-I&T$2,700
- Non-Covered Product$2,640
- ILLUCCIX$2,600
- Axumin$2,000
- FYARRO$1,500
- KEYTRUDA$1,090
- Korlym$500
How this compares
$259,719 in reported general payments places this provider in the 95th percentile of 133 medical oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 70 | $950,094 |
| CabometyxCabozantinib S-Malate | 34 | $829,054 |
| LynparzaOlaparib | 34 | $574,114 |
| XtandiEnzalutamide | 33 | $420,734 |
| Abiraterone Acetate | 63 | $31,340 |
| OrgovyxRelugolix | 12 | $30,998 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 24 | $701 |
| Prednisone | 108 | $502 |
| Tamsulosin Hcl | 20 | $387 |
| Ondansetron OdtOndansetron | 19 | $170 |
| Prochlorperazine Maleate | 18 | $160 |
| Ondansetron Hcl | 14 | $132 |
| Dexamethasone | 15 | $91 |
| Rosuvastatin Calcium | 13 | $81 |
| Atorvastatin Calcium | 12 | $66 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerNubeqa | $40,418 | $950,09470 claims |
| AstraZenecaLynparza | $14,329 | $574,11434 claims |
| Astellas Pharma US IncXtandi | $126 | $420,73433 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $10,202 | $31,34063 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 133 medical oncology providers in Minnesota.
Other medical oncology in Minneapolis
- Amy KrieMinneapolis$907K
- Charles RyanMinneapolis$99K
- Dean GesmeMinneapolis$92K
- Robert KratzkeMinneapolis$79K
- Evidio Domingo MusibayMinneapolis$38K
- Emil LouMinneapolis$11K
- Keith SkubitzMinneapolis$5K
- Alexandra RezazadehMinneapolis$3K
- Matthew NwaneriMinneapolis$3K
- Amit MahipalRochester$746K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.